Aime T. Franco, PhD, provides an overview of her discussion regarding the molecular landscape of pediatric patients with thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.
Aime T. Franco, PhD, assistant professor and investigator with the Center for Childhood Cancer Research at Children's Hospital of Philadelphia, provides an overview of her discussion regarding the molecular landscape of pediatric patients with thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.
According to Franco, the thyroid cancer space tends to be underrepresented in the research spectrum due to low mortality rates associated with the disease and available treatment options.
However, there is always more to be learned, especially in examining the differences between pediatric and adult patients with thyroid cancer.
Transcription:
0:08 | I plan to discuss some of the new findings we have looking at the genetic and molecular landscape of pediatric thyroid cancers, and how this has improved our understanding and lended insight into how pediatric tumors are similar, but also very dissimilar to adult tumors, how we can personalize and specialize our approach to our pediatric patients compared to our adult patients. But also, to get us to start thinking about the fact that pediatric patients become adult patients, and how is that going to change over their lifespan?
0:46 | We don't have all those answers yet, but I think this is something we need to start thinking about in the clinical spectrum. Not only the immediate diagnosis, but what are the long term repercussions and how do we start to think about pediatric thyroid cancer as a lifespan disease and not just something that happens only during childhood.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More